A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori

M (Brian) Fennerty, T. O G Kovacs, R. Krause, M. Haber, A. Weissfeld, N. Siepman, P. Rose

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Background: Data from large, multicenter, US studies determining the efficacy of triple therapy for the eradication of Helicobacter pylori are lacking, especially for a treatment duration of less than 14 days. Methods: Patients with H pylori infection and active duodenal ulcer disease or a history of duodenal ulcer disease within the past year were randomized to receive 30 mg of lansoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 10 or 14 days. The primary efficacy end point was the eradication of H pylori as confirmed by negative histological and culture results at 4 to 6 weeks after the completion of treatment. Results: Of 284 patients enrolled in the study from 46 US sites, 236 met the entry criteria. At 4 to 6 weeks after the end of therapy, H pylori was eradicated in 85% (96/113) of the patients receiving 14-day triple therapy and in 84% (103/123) of those receiving 10-day triple therapy by per-protocol analysis (95% confidence interval for treatment group differences, - 10.5 to 8.1; P>.05). There was also no significant difference between the 14- and 10-day treatment groups when analyzed by an intent-to-treat analysis of H pylori eradication. A similar proportion of patients in each treatment group reported an adverse event related to therapy (34% [46/136] vs 38% [56/148], respective]y). Conclusions: In patients with an active or a recent history of duodenal ulcer, lansoprazole-based triple therapy for 10 or 14 days is highly effective in the eradication of H pylori. The duration of therapy may be reduced from 14 to 10 days without a significant effect on regimen efficacy.

Original languageEnglish (US)
Pages (from-to)1651-1656
Number of pages6
JournalArchives of Internal Medicine
Volume158
Issue number15
DOIs
StatePublished - Aug 24 1998

Fingerprint

Lansoprazole
Helicobacter pylori
Pylorus
Therapeutics
Duodenal Ulcer
Duodenal Diseases
Clarithromycin
Amoxicillin
Multicenter Studies

ASJC Scopus subject areas

  • Internal Medicine

Cite this

A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. / Fennerty, M (Brian); Kovacs, T. O G; Krause, R.; Haber, M.; Weissfeld, A.; Siepman, N.; Rose, P.

In: Archives of Internal Medicine, Vol. 158, No. 15, 24.08.1998, p. 1651-1656.

Research output: Contribution to journalArticle

Fennerty, M (Brian) ; Kovacs, T. O G ; Krause, R. ; Haber, M. ; Weissfeld, A. ; Siepman, N. ; Rose, P. / A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. In: Archives of Internal Medicine. 1998 ; Vol. 158, No. 15. pp. 1651-1656.
@article{af6af6056b924bc78ba78c54738d9cf6,
title = "A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori",
abstract = "Background: Data from large, multicenter, US studies determining the efficacy of triple therapy for the eradication of Helicobacter pylori are lacking, especially for a treatment duration of less than 14 days. Methods: Patients with H pylori infection and active duodenal ulcer disease or a history of duodenal ulcer disease within the past year were randomized to receive 30 mg of lansoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 10 or 14 days. The primary efficacy end point was the eradication of H pylori as confirmed by negative histological and culture results at 4 to 6 weeks after the completion of treatment. Results: Of 284 patients enrolled in the study from 46 US sites, 236 met the entry criteria. At 4 to 6 weeks after the end of therapy, H pylori was eradicated in 85{\%} (96/113) of the patients receiving 14-day triple therapy and in 84{\%} (103/123) of those receiving 10-day triple therapy by per-protocol analysis (95{\%} confidence interval for treatment group differences, - 10.5 to 8.1; P>.05). There was also no significant difference between the 14- and 10-day treatment groups when analyzed by an intent-to-treat analysis of H pylori eradication. A similar proportion of patients in each treatment group reported an adverse event related to therapy (34{\%} [46/136] vs 38{\%} [56/148], respective]y). Conclusions: In patients with an active or a recent history of duodenal ulcer, lansoprazole-based triple therapy for 10 or 14 days is highly effective in the eradication of H pylori. The duration of therapy may be reduced from 14 to 10 days without a significant effect on regimen efficacy.",
author = "Fennerty, {M (Brian)} and Kovacs, {T. O G} and R. Krause and M. Haber and A. Weissfeld and N. Siepman and P. Rose",
year = "1998",
month = "8",
day = "24",
doi = "10.1001/archinte.158.15.1651",
language = "English (US)",
volume = "158",
pages = "1651--1656",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "15",

}

TY - JOUR

T1 - A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori

AU - Fennerty, M (Brian)

AU - Kovacs, T. O G

AU - Krause, R.

AU - Haber, M.

AU - Weissfeld, A.

AU - Siepman, N.

AU - Rose, P.

PY - 1998/8/24

Y1 - 1998/8/24

N2 - Background: Data from large, multicenter, US studies determining the efficacy of triple therapy for the eradication of Helicobacter pylori are lacking, especially for a treatment duration of less than 14 days. Methods: Patients with H pylori infection and active duodenal ulcer disease or a history of duodenal ulcer disease within the past year were randomized to receive 30 mg of lansoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 10 or 14 days. The primary efficacy end point was the eradication of H pylori as confirmed by negative histological and culture results at 4 to 6 weeks after the completion of treatment. Results: Of 284 patients enrolled in the study from 46 US sites, 236 met the entry criteria. At 4 to 6 weeks after the end of therapy, H pylori was eradicated in 85% (96/113) of the patients receiving 14-day triple therapy and in 84% (103/123) of those receiving 10-day triple therapy by per-protocol analysis (95% confidence interval for treatment group differences, - 10.5 to 8.1; P>.05). There was also no significant difference between the 14- and 10-day treatment groups when analyzed by an intent-to-treat analysis of H pylori eradication. A similar proportion of patients in each treatment group reported an adverse event related to therapy (34% [46/136] vs 38% [56/148], respective]y). Conclusions: In patients with an active or a recent history of duodenal ulcer, lansoprazole-based triple therapy for 10 or 14 days is highly effective in the eradication of H pylori. The duration of therapy may be reduced from 14 to 10 days without a significant effect on regimen efficacy.

AB - Background: Data from large, multicenter, US studies determining the efficacy of triple therapy for the eradication of Helicobacter pylori are lacking, especially for a treatment duration of less than 14 days. Methods: Patients with H pylori infection and active duodenal ulcer disease or a history of duodenal ulcer disease within the past year were randomized to receive 30 mg of lansoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 10 or 14 days. The primary efficacy end point was the eradication of H pylori as confirmed by negative histological and culture results at 4 to 6 weeks after the completion of treatment. Results: Of 284 patients enrolled in the study from 46 US sites, 236 met the entry criteria. At 4 to 6 weeks after the end of therapy, H pylori was eradicated in 85% (96/113) of the patients receiving 14-day triple therapy and in 84% (103/123) of those receiving 10-day triple therapy by per-protocol analysis (95% confidence interval for treatment group differences, - 10.5 to 8.1; P>.05). There was also no significant difference between the 14- and 10-day treatment groups when analyzed by an intent-to-treat analysis of H pylori eradication. A similar proportion of patients in each treatment group reported an adverse event related to therapy (34% [46/136] vs 38% [56/148], respective]y). Conclusions: In patients with an active or a recent history of duodenal ulcer, lansoprazole-based triple therapy for 10 or 14 days is highly effective in the eradication of H pylori. The duration of therapy may be reduced from 14 to 10 days without a significant effect on regimen efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0032563694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032563694&partnerID=8YFLogxK

U2 - 10.1001/archinte.158.15.1651

DO - 10.1001/archinte.158.15.1651

M3 - Article

C2 - 9701099

AN - SCOPUS:0032563694

VL - 158

SP - 1651

EP - 1656

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 15

ER -